NANOFIBER TECHNOLOGY FOR CONTROLLING STEM CELL FUNCTIONS AND TISSUE ENGINEERING - Micro and Nanotechnologies in Engineering Stem Cells and Tissues - page 47

28. Le Blanc K, Pittenger M. Mesenchymal stem cells: progress toward promise. Cyto-
therapy 2005;7:36-45.
29. Zuk PA, Zhu M, Mizuno H, Huang J, Futrell JW, Katz AJ, Benhaim P, Lorenz HP,
Hedrick MH. Multilineage cells from human adipose tissue: implications for cell-based
therapies. Tissue Eng 2001;7:211.
30. Bottai D, Fiocco R, Gelain F, Defilippis L, Galli R, Gritti A, Vescovi LA. Neural stem
cells in the adult nervous system. J Hematother Stem Cell Res 2003;12:655.
31. Beyer Nardi N, da Silva Meirelles L. Mesenchymal stem cells: isolation, in vitro
expansion and characterization. Handb Exp Pharmacol 2006;174:249-282.
32. Conget PA, Minguell JJ. Phenotypical and functional properties of human bone marrow
mesenchymal progenitor cells. J Cell Physiol 1999;181:67-73.
33. Ries C, Egea V, KarowM, Kolb H, JochumM, Neth P. MMP-2, MT1-MMP, and TIMP-2
are essential for the invasive capacity of human mesenchymal stem cells: differential
regulation by inflammatory cytokines. Blood 2007;109:4055-4063.
34. Le Blanc K. Immunomodulatory effects of fetal and adult mesenchymal stem cells.
Cytotherapy 2003;5:485-489.
35. Lu L, Shen RN, Broxmeyer HE. Stem cells from bone marrow, umbilical cord blood and
peripheral blood for clinical application: current status and future application. Crit Rev
Oncol Hematol 1996;22:61-78.
36. Richards M, Tan SP, Tan JH, Chan WK, Bongso A. The transcriptome profile of human
embryonic stem cells as defined by SAGE. Stem Cells 2004;22:51-64.
37. Thomson JA, Itskovitz-Eldor J, Shapiro SS, Waknitz MA, Swiergiel JJ, Marshall VS,
Jones JM. Embryonic stem cell lines derived from human blastocysts. Science 1998;282
(5391):1145-1147.
38. Chambers I, Smith A. Self-renewal of teratocarcinoma and embryonic stem cells.
Oncogene 2004;23:7150-7160.
39. Reubinoff BE, Pera MF, Fong CY, Trounson A, Bongso A. Embryonic stem cell lines
from human blastocysts: somatic differentiation in vitro. Nat Biotechnol 2000;18:
399-404.
40. Mitsui K, Tokuzawa Y, Itoh H, Segawa K, Murakami M, Takahashi K, et al. The
homeoprotein Nanog is required for maintenance of pluripotency in mouse epiblast and
ES cells. Cell 2003;113:631-642.
41. Judson RL, Babiarz JE, Venere M, Blelloch R. Embryonic stem cell-specific microRNAs
promote induced pluripotency. Nat Biotechnol 2009;27:459-461.
42. Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic
and adult fibroblast cultures by defined factors. Cell 2006;126:663-676.
43. Sendtner M. Stem cells: tailor-made diseased neurons. Nature 2009;457:269-270.
44. Martino S, D'Angelo F, Armentano I, Kenny JM, Orlacchio A. Stem cell-biomaterial
interactions for regenerative medicine. Biotechnol Adv 2011;30:338-351.
45. Zhao T, Xu Y. Immunogenicity of induced pluripotent stem cells. Nature 2011;474
(7350):212-215.
46. Singh S. Nanomedicine-nanoscale drugs and delivery systems. J Nanosci Nanotechnol
2010;10(12):7906-7918.
47. Kumbar SG, Nair LS, Bhattacharyya S, Laurencin CT. Polymeric nanofibers as novel
carriers for the delivery of therapeutic molecules. J Nanosci Nanotechnol 2006;6
(9-10):2591-2607.